PROTAC Bifunctional Complex Degrades CDK4/6
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK4/6 inhibitors have limitations in effectively targeting and degrading CDK4/6 proteins, which are crucial for controlling cell cycle progression and are often abnormally active in cancer cells, leading to incomplete tumor cell arrest and potential resistance.
Innovation Solution
A novel bifunctional complex is developed using PROTAC technology, comprising a protein binding moiety (PBM) and a protein degradation moiety (PDM) linked by a suitable linker, specifically targeting and degrading CDK4/6 proteins, thereby inhibiting their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK4/6 inhibitors are used, then cell cycle progression is inhibited, but the inhibition is incomplete and leads to potential resistance
Solution Approach 1:
The patent extracts the target protein CDK4/6 from the cell cycle system and removes it completely through degradation, rather than merely inhibiting its activity. The PROTAC molecule pulls CDK4/6 out of the functional system and eliminates it via the ubiquitin-proteasome pathway, ensuring complete removal and preventing resistance development.
Solution Approach 2:
The patent introduces an intermediary system (ubiquitin-proteasome system) to mediate the degradation of CDK4/6. The PROTAC molecule acts as a bridge that connects CDK4/6 to the ubiquitin-proteasome degradation machinery, enabling controlled and complete degradation of the target protein through this intermediary pathway.
2Productivity
If CDK4/6 activity is inhibited, then cell proliferation is blocked, but protein degradation is not achieved
Solution Approach 1:
The PROTAC molecule extracts CDK4/6 protein from the cell and directs it to the ubiquitin-proteasome system for complete degradation. This is achieved through the bifunctional design where PBM binds to CDK4/6 and PDM recruits the degradation system, physically removing and destroying the target protein rather than just blocking its activity.
Solution Approach 2:
The patent uses the ubiquitin-proteasome system as an intermediary degradation pathway. The PROTAC molecule mediates between CDK4/6 and this degradation system, facilitating the transfer of CDK4/6 to the proteasome for complete protein breakdown, thereby achieving substantial loss of the target substance.
3Reliability
If selective CDK4/6 inhibition is achieved, then therapeutic efficacy is improved, but device complexity increases due to PROTAC structure
Solution Approach 1:
The patent merges two distinct functional moieties (PBM for target binding and PDM for degradation recruitment) into a single bifunctional PROTAC molecule. This combination allows the molecule to simultaneously perform target recognition and degradation initiation, improving therapeutic efficacy while consolidating multiple functions into one molecular entity.
Solution Approach 2:
The PROTAC molecule exhibits multi-functionality by combining target protein binding capability with degradation system recruitment capability in a single molecule. This universal design allows one compound to perform multiple roles: specific target recognition, bridging to degradation machinery, and initiating complete protein degradation, thereby improving efficacy despite increased molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional complex effectively arrests cell cycle progression by selectively degrading CDK4/6 proteins, offering enhanced therapeutic efficacy in treating cancers such as breast, rectal, colon, lung, multiple myeloma, liver, and ovarian cancers by ensuring complete tumor cell arrest.
Implementation Method 1
The ubiquitin-proteasome system (UPS) is a main pathway for intracellular protein degradation... Ubiquitin is attached to a target protein via ligase, and the target protein is transported into proteasome for degradation.
Data Source
AI summary
The present disclosure discloses a compound as represented by formula (I) or a pharmaceutically acceptable salt, a solvate or a stereoisomer thereof, that can be represented by the following structureAs a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), the compounds of the present disclosure may be used for treating or preventing a disease at least partially modulated by CDK4/6.